MannKind Corporation MNKD
Regular-session close
After hours · Nov 20, 5:11 PM ET
- YTD
- -32.10%
- 1 year
- -22.54%
5D -0.21 (-5.13%)
- Market cap
- 1.24B
- Revenue (ttm)
- 413.37M
- Profit margin
- -18.10%
- EPS (ttm)
- -0.24
- Shares out
- 321.64M
- Forward P/E
- 24.44
- YTD return
- -32.10%
- 1-year return
- -22.54%
- 50-day average
- 3.57
- 200-day average
- 3.61
- Volume
- 4.18M
- Avg volume
- 3.95M
- Open
- 3.90
- Previous close
- 3.95
- Day's range
- 3.83 – 4.08
- 52-week range
- 2.28 – 6.21
- Beta
- 1.09
- Analysts
- Strong Buy
- Price target
- 8.33 (+116.5%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 1.75B
- PEG ratio
- 4.39
- Price / sales
- 3.00
- Revenue growth
- 24.00%
- Free cash flow
- -6.02M
- Total cash
- 96.61M
- Total debt
- 578.12M
- Short % of float
- 8.26%
Fundamental scorecard
6 of 25 checks passed on MNKD’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 5.00
- Target (mean)
- 8.33
- Target (high)
- 13.00
- Strong buy0
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.05667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.01 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.06556 | -0.01 | +0.06 | +84.75% |
| Aug 5, 2026 | Jun 30, 2026 | -0.0075 | -0.06 | -0.05 | -700.00% |
| May 6, 2026 | Mar 31, 2026 | -0.02 | -0.05 | -0.03 | -150.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.01 | -0.05 | -0.04 | -400.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.01 | 0.03 | +0.02 | +200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Nov 6, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Oct 20, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Oct 19, 2026 | Chardan Capital | init | — | Buy |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 11, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mannkindcorp.com
News
Should You Buy MannKind (MNKD) After Golden Cross?
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5
Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10
Your note
Sign in to keep a note on MNKD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AHUJA AJAY M.D. | Officer | Stock Award(Grant) | Nov 10, 2025 | 318,200 |
| BINDER STEVEN B | Director | Sale | Sep 24, 2026 | 713,258 |
| CASTAGNA MICHAEL E | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 14, 2026 | 2,433,780 |
| CONSIGLIO RONALD JOSEPH | Director | Stock Award(Grant) | May 19, 2026 | 132,342 |
| HOOPER ANTHONY C | Director | Stock Award(Grant) | Feb 26, 2026 | 236,153 |
| MARASCO DOMINIC | Officer | Stock Award(Grant) | May 19, 2026 | 344,246 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.23% | 32,919,459 | 126.74M | Sep 29, 2026 |
| Rubric Capital Management LP | 9.15% | 29,430,000 | 113.31M | Sep 29, 2026 |
| Frazier Life Sciences Management, L.P. | 4.90% | 15,755,491 | 60.66M | Sep 29, 2026 |
| State Street Corporation | 4.69% | 15,096,712 | 58.12M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.40% | 14,167,827 | 54.55M | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.50% | 8,052,721 | 31.00M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 9,327,332 | 35.91M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.55% | 8,188,148 | 31.52M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.23% | 7,165,914 | 27.59M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.41% | 4,522,701 | 17.41M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.10% | 3,526,693 | 13.58M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.05% | 3,367,944 | 12.97M | Aug 30, 2026 |
